rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
rs1057519725
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
23182985 |
2013 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
|
24558511 |
2014 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
|
19679400 |
2009 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs112445441
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
|
21228335 |
2011 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
|
19114683 |
2009 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
rs112445441
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
|
22392911 |
2012 |